Journal
NATURE COMMUNICATIONS
Volume 13, Issue 1, Pages -Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41467-022-30088-y
Keywords
-
Categories
Funding
- Lord Mayor's Charitable Foundation
- Ray William Houston Trust
- Australian Partnership for Preparedness Research for Infectious Disease Emergencies (APPRISE)
- National Health and Medical Research Council Centre of Research Excellence (NHMRC CRE)
- Australian Partnership for Preparedness Research on Infectious Disease Emergencies (APPRISE) [1116530]
- Snow Medical Foundation
- Jack Ma Foundation
- A2 Milk Company
- Austin Health Foundation
- NIAID, NIH [HHSN272201400008C]
- NHMRC Leadership Investigator Grant [1173871]
- Research Grants Council of the Hong Kong Special Administrative Region, China [T11-712/19-N]
- MRFF Award [1202445]
- NIH contract CIVC-HRP (HHS-NIH-NIAID-BAA2018)
- NHMRC Senior Principal Research Fellowship [1117766]
- NHMRC Emerging Leadership Level 1 Investigator Grant [1194036]
- NHMRC Early Career Fellowships [1160333, 1160963, 1139902]
- NIH NIAID [R01 AI136514-03]
- ALSAC at St. Jude
- Melbourne Research Scholarship from The University of Melbourne
- Melbourne International Research Scholarship (MIRS) from The University of Melbourne
- Melbourne International Fee Remission Scholarship (MIFRS) from The University of Melbourne
Ask authors/readers for more resources
This study compares the immune response in peripheral blood and respiratory samples of COVID-19 patients, revealing differential immune responses between these compartments. Specific antibodies against SARS-CoV-2 are more pronounced in respiratory specimens and correlate with neutralization activity. Additionally, inflammation, immune subsets, and drug therapy impact the immune response.
The immune response to SARS-CoV-2 infection is variable but has been linked to prognosis and the development of severe immunopathology. Here the authors assess a range of immune parameters in both peripheral blood and respiratory samples, providing a comparative assessment of the immune response between these compartments and their potential impact on immune-pathogenesis. Respiratory tract infection with SARS-CoV-2 results in varying immunopathology underlying COVID-19. We examine cellular, humoral and cytokine responses covering 382 immune components in longitudinal blood and respiratory samples from hospitalized COVID-19 patients. SARS-CoV-2-specific IgM, IgG, IgA are detected in respiratory tract and blood, however, receptor-binding domain (RBD)-specific IgM and IgG seroconversion is enhanced in respiratory specimens. SARS-CoV-2 neutralization activity in respiratory samples correlates with RBD-specific IgM and IgG levels. Cytokines/chemokines vary between respiratory samples and plasma, indicating that inflammation should be assessed in respiratory specimens to understand immunopathology. IFN-alpha 2 and IL-12p70 in endotracheal aspirate and neutralization in sputum negatively correlate with duration of hospital stay. Diverse immune subsets are detected in respiratory samples, dominated by neutrophils. Importantly, dexamethasone treatment does not affect humoral responses in blood of COVID-19 patients. Our study unveils differential immune responses between respiratory samples and blood, and shows how drug therapy affects immune responses during COVID-19.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available